Peptides for ALS: the neuroprotection approach - A Clinical Persp...

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

ALS patients face a severe prognosis, and current pharmaceutical interventions offer limited benefit, prompting exploration into neuroprotective peptides. Peptides like Cerebrolysin, MOTS-c, and FGL demonstrate preclinical promise by addressing mitochondrial dysfunction, supporting neuronal health, and enhancing neurotrophic pathways, though human efficacy and optimal dosing remain subjects of ongoing research and clinical trials.

Peptides for ALS: The Neuroprotection Approach

Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease, and the median survival from symptom onset is only 2 to 5 years [1]. While Riluzole and Edaravone offer modest benefits, extending life by a few months at best, they don't halt the relentless progression of motor neuron death [2] [3]. This grim reality fuels the search for novel therapeutic strategies, and peptides, with their targeted mechanisms and favorable safety profiles, are emerging as promising candidates for neuroprotection in ALS.

One compelling peptide in this context is MOTS-c, a mitochondrial-derived peptide that primarily acts to improve metabolic homeostasis. While not directly targeting motor neurons, MOTS-c has shown capabilities in ameliorating mitochondrial dysfunction, a key pathological hallmark in ALS [4]. In preclinical models of neurodegeneration, MOTS-c has been observed to reduce oxidative stress and improve cellular energy production. A typical dosing regimen for MOTS-c in research settings might involve 10-20 mg subcutaneously per week, though human trials for ALS specifically are still nascent.

Another peptide garnering significant attention is Cerebrolysin, a porcine brain-derived peptide mixture comprising various neurotrophic factors and amino acids. It's been studied for its neuroprotective and neurorestorative properties in various neurological disorders, including stroke and traumatic brain injury [5]. In ALS, Cerebrolysin's proposed mechanism involves enhancing neuronal survival, reducing excitotoxicity, and modulating inflammation. Clinical observations suggest that a daily intravenous infusion of 10-30 mL for 10-20 days, followed by maintenance doses, might offer some symptomatic relief and potentially slow disease progression in a subset of patients, particularly those in earlier stages. However, its broad composition means pinpointing a single active ingredient is difficult, and individual responses vary significantly; some patients report mild improvements in daily function, while others experience no noticeable benefit.

FGL (N-acetyl-Pro-Gly-Pro-Leu-Leu-Ala-Gly-Arg-Lys), a synthetic peptide derived from the neurotrophic factor FGF-2, represents a more targeted approach. FGL has demonstrated an ability to cross the blood-brain barrier and promote neurite outgrowth and synaptogenesis [6]. In animal models of neurodegeneration, FGL has shown promise in preserving neuronal integrity and improving cognitive function. For ALS, the rationale for FGL lies in its potential to support the health of remaining motor neurons and potentially foster new connections. While specific human dosing for ALS isn't established, preclinical studies often use doses in the range of 1-5 mg/kg administered intraperitoneally. The challenge with FGL, like many novel peptides, is translating preclinical success to human efficacy, especially given the complex and multifactorial nature of ALS.

Comparing these approaches, Cerebrolysin offers a broad-spectrum neurotrophic effect, akin to casting a wide net, which might be beneficial given the multifaceted pathology of ALS. However, its complex composition makes it challenging to isolate specific mechanisms of action and optimize dosing. In contrast, MOTS-c and FGL represent more targeted interventions. MOTS-c addresses mitochondrial dysfunction, a fundamental cellular problem in ALS, while FGL aims to directly support neuronal structure and connectivity. The advantage of a more targeted peptide like FGL is the potential for higher specificity and fewer off-target effects, but it also means it might only address one aspect of a complex disease.

It's crucial to acknowledge the limitations. While these peptides show promise in preclinical studies, human trials for ALS are often slow, underfunded, and complicated by the heterogeneity of the disease. Furthermore, the blood-brain barrier poses a significant challenge for many peptide therapeutics, requiring specialized delivery methods or peptides engineered for improved permeability. For example, while MOTS-c can cross the blood-brain barrier to some extent, optimizing its brain bioavailability for ALS remains an active area of research.

The neuroprotection strategy with peptides in ALS isn't about curing the disease; it's about preserving existing motor neurons, slowing their degeneration, and improving the quality of life for as long as possible. The goal is to extend the period of functional independence, not necessarily to reverse established damage. This is a critical distinction clinicians must convey to patients and their families.

A specific clinical takeaway is that for patients with early-stage ALS, considering adjunctive therapies like Cerebrolysin (10-30 mL IV daily for 10-20 days, then maintenance) or exploring participation in clinical trials for peptides like MOTS-c or FGL may offer a neuroprotective strategy, though expectations for significant functional recovery should be managed carefully, with a focus on slowing progression rather than reversal.

References